Milatuzumab
Based on 4 publication(s) in Google Scholar
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.
For research use only. We do not sell to patients.
- Purity: 99.39%
- CAS No.: 899796-83-9
- Molecular Weight:145.66 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Milatuzumab
More-
Cell Imaging/Staining
-
WB
-
IF
-
Flow Cytometry
-
Flow Cytometry
Biological Activity
Human IgG1 kappa
Human
CD74
Milatuzumaba (5 μg/mL; 8-48 h) enhances cell death in MCL cell lines and primary patient tumor cells[1].
Milatuzumaba (5 μg/mL; 0.5-2 h) mediates the cytotoxicity partially depending on generation of ROS and loss of mitochondrial transmembrane potential in Jeko, Mino, and SP-53 cells[1].
Milatuzumaba (5 μg/mL; 4 h) inhibits NF-κB pathway and induces cell apoptosis with independent of caspase cleavage, Bcl-2 family member dysregulation, or induction of autophagy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jeko and Mino cells
-
Concentration:5 μg/mL
-
Incubation Time:4 hours
-
Result:Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.
-
Cell Line:MCL cell lines and primarypatient tumor cells
-
Concentration:5 μg/mL
-
Incubation Time:8, 24, and 48 hours
-
Result:Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells.
-
Cell Line:Jeko, Mino, and SP-53 cells
-
Concentration:5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h
-
Incubation Time:0.5, 1, 1.5, and 2 hours
-
Result:Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Jeko mouse model[1]
-
Dosage:15 mg/kg/day; with or without 15 mg/kg Rituximab
-
Administration:Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
-
Result:Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized hu-CD74-ECD-His can bind Milatuzumab. The EC50 for this effect is 3.941 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD74 (red) with Milatuzumab (anti-CD74) (HY-P99731). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 899796-83-9
-
Appearance Liquid
-
Molecular Weight 145.66 kDa
-
Color Colorless to light yellow
-
SMILES
[Milatuzumab]
-
Synonyms
hLL1; MEDI-115
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
CD74 Blockade Disrupts Endothelial Migrasome Signaling to Prevent Inflammatory Macrophage Differentiation and Inhibit Atherosclerotic Progression. [Abstract]2025 Jun 23:e02838. PMID: 40548932
Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838. [Abstract]
HCAEC cells were treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) for 12 hours, stained with 1 µg/ml WGA-Alexa 488 and CD80, and observed under a confocal microscope.
Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838. [Abstract]
Western blot analysis of migratory bodies and M1 macrophage-related markers in HCAEC cells treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) was performed.
Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838. [Abstract]
Immunofluorescence images showing M1 macrophages and migrasomes in Control, AS, and AS_Anti CD74 (Milatuzumab: 15 mg/kg) groups. Red: WGA‐594 (labeling migrasomes); Green: iNOS (labeling M1 macrophages); Magenta: CD206 (labeling M2 macrophages); Blue: DAPI (nuclei).
-
J Immunother Cancer
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. [Abstract]2024 Aug 6;12(8):e009024. PMID: 39107132
Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024. [Abstract]
Macrophages derived from THP-1 cells treated with anti-CD74 (Milatuzumab) were co-cultured. Phagocytic efficiency was quantified as the percentage of dual-fluorescence-positive macrophages (upper right quadrant).
Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024. [Abstract]
Flow cytometry was used to detect differences in phagocytic function among the control group, cisplatin group, and combination therapy group with anti-CD74 Ab (5 µg/mL). THP-1-derived macrophages were co-cultured with SiHa cells.
-
-
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)